APOC3 and myocardial ischemia: ApoCIII, a component of TRLs, elevates serum triglyceride levels by inhibitingLpL activity, reducing TG lipolysis, and enhancing hepatic TG synthesis [70].Studies suggest that apoCIII loss-of-function heterozygotes exhibit lifelong 43%lower plasma RC levels, mediating a 37% reduction in ischemic vascular disease(IVD) risk and a 54% reduction in IHD risk [71].